119 related articles for article (PubMed ID: 8543977)
1. Targeted delivery of antineoplastic agent to bone: biodistribution studies of technetium-99m-labeled gem-bisphosphonate conjugate of methotrexate.
Hosain F; Spencer RP; Couthon HM; Sturtz GL
J Nucl Med; 1996 Jan; 37(1):105-7. PubMed ID: 8543977
[TBL] [Abstract][Full Text] [Related]
2. Targeted antiosteosarcoma methotrexate-bisphosphonate conjugate induces apoptosis of osteosarcoma cells in vitro.
Yang XN; Zeng JC; Song YC; Zhang H; Pei FX
Eur Rev Med Pharmacol Sci; 2014; 18(15):2116-23. PubMed ID: 25070815
[TBL] [Abstract][Full Text] [Related]
3. High-dose methotrexate in fibroblastic osteosarcoma.
Chowbay B; Siong KK
Ann Pharmacother; 2001 Dec; 35(12):1669. PubMed ID: 11793640
[No Abstract] [Full Text] [Related]
4. Preclinical investigations of drug and radionuclide conjugates of bisphosphonates for the treatment of metastatic bone cancer.
El-Mabhouh A; Angelov C; McEwan A; Jia G; Mercer J
Cancer Biother Radiopharm; 2004 Oct; 19(5):627-40. PubMed ID: 15650456
[TBL] [Abstract][Full Text] [Related]
5. New bone-seeking agent: animal study of Tc-99m-incadronate.
Shigematsu M; Shomi S; Iwao H; Ochi H
Ann Nucl Med; 2002 Feb; 16(1):55-9. PubMed ID: 11922209
[TBL] [Abstract][Full Text] [Related]
6. A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma.
Johansson ÅM; Hill N; Perisoglou M; Whelan J; Karlsson MO; Standing JF
Ther Drug Monit; 2011 Dec; 33(6):711-8. PubMed ID: 22105588
[TBL] [Abstract][Full Text] [Related]
7. A 99mTc-labeled gemcitabine bisphosphonate drug conjugate as a probe to assess the potential for targeted chemotherapy of metastatic bone cancer.
El-Mabhouh AA; Angelov CA; Cavell R; Mercer JR
Nucl Med Biol; 2006 Aug; 33(6):715-22. PubMed ID: 16934690
[TBL] [Abstract][Full Text] [Related]
8. Delayed renal excretion of methotrexate after a severe anaphylactic reaction to methotrexate in a child with osteosarcoma.
Ozguven AA; Uysal K; Gunes D; Koroglu T; Gurcu O; Olgun N
J Pediatr Hematol Oncol; 2009 Apr; 31(4):289-91. PubMed ID: 19346884
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma.
Colom H; Farré R; Soy D; Peraire C; Cendros JM; Pardo N; Torrent M; Domenech J; Mangues MA
Ther Drug Monit; 2009 Feb; 31(1):76-85. PubMed ID: 19077931
[TBL] [Abstract][Full Text] [Related]
10. Technetium-99m-labeled phosphonic acid analog of serine: bone uptake.
Surh Y; Spencer RP; Spitznagle LA; Hosain F; Lejczak B
J Nucl Med; 1986 Jun; 27(6):847-9. PubMed ID: 3712097
[TBL] [Abstract][Full Text] [Related]
11. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma: analysis of the literature.
Bielack SS; Beron G; Winkler K
Cancer; 1997 Aug; 80(3):516-8. PubMed ID: 9241087
[No Abstract] [Full Text] [Related]
12. Activity in the gastrointestinal tract after administration of bone-seeking radiopharmaceuticals. Experimental studies in mice.
Cronhjort M; Jonsson C; Nilsson SO; Garmelius B; Jacobsson H
Acta Radiol; 1996 Sep; 37(5):785-90. PubMed ID: 8915294
[TBL] [Abstract][Full Text] [Related]
13. Bone-targeting dendrimer for the delivery of methotrexate and treatment of bone metastasis.
Yamashita S; Katsumi H; Sakane T; Yamamoto A
J Drug Target; 2018 Nov; 26(9):818-828. PubMed ID: 29376757
[TBL] [Abstract][Full Text] [Related]
14. Can high dose methotrexate be continued after severe hypersensitivity reaction?
Marzollo A; Bisogno G
Pediatr Blood Cancer; 2014 Jun; 61(6):1139. PubMed ID: 24265186
[No Abstract] [Full Text] [Related]
15. A conjugate of gemcitabine with bisphosphonate (Gem/BP) shows potential as a targeted bone-specific therapeutic agent in an animal model of human breast cancer bone metastases.
El-Mabhouh AA; Nation PN; Abele JT; Riauka T; Postema E; McEwan AJ; Mercer JR
Oncol Res; 2011; 19(6):287-95. PubMed ID: 21776824
[TBL] [Abstract][Full Text] [Related]
16. The bisphosphonate dilemma.
Koyano H; Schimizu T; Shishiba Y
J Nucl Med; 1995 Apr; 36(4):705-6. PubMed ID: 7699469
[No Abstract] [Full Text] [Related]
17. Hypersensitivity reaction to high-dose methotrexate and successful rechallenge in a pediatric patient with osteosarcoma.
Scott JR; Ward DA; Crews KR; Panetta JC; Navid F
Pediatr Blood Cancer; 2014 Feb; 61(2):373-5. PubMed ID: 23955991
[TBL] [Abstract][Full Text] [Related]
18. Extraskeletal localization of 99mTc-labeled bone-seeking tracers in bone scintigraphy.
Arend SM; Pauwels EK; Arndt JW; Meinders AE
Neth J Med; 1994 Oct; 45(4):177-91. PubMed ID: 7808581
[TBL] [Abstract][Full Text] [Related]
19. Animal studies of 99mTc-i-PIDP: a new bone imaging agent.
Wang Y; Luo S; Lin J; Qiu L; Cheng W; Zhai H; Nan B; Ye W; Xia Y
Appl Radiat Isot; 2011 Sep; 69(9):1169-75. PubMed ID: 21507669
[TBL] [Abstract][Full Text] [Related]
20. [Bone scintigraphy in assessing the success of chemotherapy in osteosarcoma].
Knop J; Stritzke P; Montz R; Delling G; Winkler K
Nuklearmedizin; 1985 Apr; 24(2):75-81. PubMed ID: 2410864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
